

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/022264-2021>

Not applicable

New Velindre Cancer Centre MIM Project

Velindre University NHS Trust

F14: Notice for changes or additional information

Notice identifier: 2021/S 000-022264

Procurement identifier (OCID): ocds-h6vhtk-02a90b

Published 8 September 2021, 1:05pm

Section I: Contracting authority/entity

I.1) Name and addresses

Velindre University NHS Trust

Transforming Cancer Services Programme, Velindre Cancer Centre, Whitchurch

Cardiff

CF14 2TL

Contact

Mark Ash, Assistant Project Director – Finance & Commercials

Email

TCS.Contracts@wales.nhs.uk

Telephone

+44 2920196852

Country

United Kingdom

NUTS code

UKL22 - Cardiff and Vale of Glamorgan

Internet address(es)

Main address

<http://www.transformingcancerservices.wales>

Buyer's address

https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

New Velindre Cancer Centre MIM Project

II.1.2) Main CPV code

- 45215140 - Hospital facilities construction work

II.1.3) Type of contract

Works

II.1.4) Short description

Velindre University NHS Trust (the "Contracting Authority") is seeking tenders for the design, construction, finance and maintenance of the New Velindre Cancer Centre (the "Project") which will be situated on a greenfield site, owned by the Contracting Authority, at Whitchurch, North Cardiff. The Contracting Authority proposes to procure the Project through the Welsh Government's Mutual Investment Model ("MIM") which is a specific model for procuring public private partnerships in Wales.

The new state of the art cancer centre facility (anticipated to be approximately 32,000m²) is to be designed, constructed, financed and maintained by the special purpose vehicle ("Project Co") established by the economic operator who is awarded the contract (the "Successful Participant") to support the vision and aims detailed within the Velindre NHS Trust publication 'Velindre Cancer Strategy 2016-2026, Shaping our future together'.

Section VI. Complementary information

VI.6) Original notice reference

Notice number: [2021/S 000-008602](#)

Section VII. Changes

VII.1) Information to be changed or added

VII.2) Other additional information

Amendment to Additional Information VI.3)Full Notice Text.Prior to “NOTE: The authority is using eTenderwales to carry out this procurement process”,amended to read as follows: The Contracting Authority(‘the Authority’)is undertaking a competitive dialogue procedure in order to procure the contract for the design,build,finance & maintenance of the New Velindre Cancer Centre.Economic operators are asked to express their interest in the procurement by 14/06/2021 by submitting a completed PQQ response addressed to the Authority at Sell2Wales.Further information on the requirements for the pre-qualification stage(including the evaluation of completed PQQ Responses)is set out in the Descriptive Document.After the evaluation of each completed PQQ response,an invitation to participate in dialogue will be issued to three(3)shortlisted economic operators.The Authority reserves the right to make revisions to the documentation (including the PQQ & Descriptive Document) &/or the context,process,timing & structure of the procurement process at any time.No additional time in relation to submission deadlines will be granted,following notification of any such revision,unless expressly notified by the Authority.Reference in this notice to ProjectCo carrying out works or services should be read as ProjectCo carrying out or procuring the carrying out of those works & services.The public sector equity participant("WGCo")will undertake due diligence & an equity investment appraisal independently of procurement of the Project & will have no obligation to invest the quantum specified.It follows therefore that economic operators will be required to submit bids which are funded on the basis that no investment is made by the WGCo.Where WGCo does invest equity,it will do so on essentially the same terms as the private sector.If selected to proceed to the Invitation to Participate in Dialogue stage,economic operators will be required to sign a confidentiality & non-collusion letter with the Authority.The estimated total value stated in section II.1.5 & section II.2.6 has been based on the estimated total annual service payments payable under the contract.The construction CapEx is anticipated to be in the region of 200,000,000 GBP CapEx.Economic operators participate in the procurement process entirely at their own risk & the Authority does not accept any liability in respect of costs incurred in relation to this procurement process,other than as specifically provided for on the terms set out in a bid cost letter available on request by emailing:TCS.Contracts@wales.nhs.uk.Broadly,the bid cost letter provides that the Authority shall reimburse economic operators invited to participate in dialogue a capped proportion of participation costs in three specific scenarios:1)in circumstances where such economic operator is notified of the Authority’s decision to award the contract to another economic operator;2)in circumstances where the procurement competition is cancelled due to a change in Welsh Government policy; or3)in circumstances where the procurement competition is deemed to be cancelled by the Authority & the contract has not been entered into within 12 months of the anticipated date of financial close of the Project.The Authority’s liability is capped at 1,300,000 GBP

per participant (such sum being an aggregate amount across all entities within any bidding consortia).The detailed terms & conditions on which reimbursement can be claimed are set out in the bid cost letter.The Authority reserves the right in its absolute discretion to not proceed with the procurement.The Authority may elect to discontinue or suspend the procurement at any time.Other than as set out in the bid cost letter referred to above,the Authority may do so without responsibility or liability to any interested party resulting from such decision not to proceed,discontinuation or suspension,including any liability for any costs or expenditure incurred by,or inconvenience caused.